antisense

UMich's Arul Chinnaiyan plans to use the funding to develop new tools and technologies to identify biomarkers for cancer diagnosis and treatment.

The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.

NEW YORK (GenomeWeb) — Isis Pharmaceuticals and Santaris Pharma are currently negotiating a settlement to their roughly three-year-old patent-infringement lawsuit and believe there is "strong potential to settle" the litigation instead of going to trial, according to court documents filed this mo

NEW YORK (GenomeWeb) – While its primary focus remains on a class of novel cell membrane-disrupting antimicrobials, privately held Lakewood-Amedex is ramping up work on proprietary, orally delivered antisense molecules, with an eye to tackling influenza and, eventually, other viral diseases.

NEW YORK (GenomeWeb) – Marina Biotech this week took another step toward reestablishing itself as a player in the nucleic acids drug sector, regaining compliance with US Securities and Exchange Commission financial reporting requirements with the submission of the requisite information for 2012,

NEW YORK (GenomeWeb) – The National Institutes of Health this month announced two related funding opportunities for small businesses developing platform delivery technologies for nucleic acid therapeutics.

People in the News: Art Krieg

Premium

RNA drug developer Sarepta Therapeutics disclosed that its CSO, Art Krieg, has been terminated from his position at the company.
Details about the termination were not made public.

NEW YORK (GenomeWeb) – Researchers from Isis Pharmaceuticals this week published new data demonstrating the ability of a novel GalNAc conjugate to boost the potency of antisense oligonucleotides (ASOs) — including two it currently has in human trials — by as much as 10 fold in mice.

A US District Court last week denied Santaris Pharma's second bid to have a patent-infringement lawsuit filed against it by Isis Pharmaceuticals thrown out, ruling that the company again failed to establish that its allegedly infringing activities were protected by a US statute t

Isis Pharmaceuticals this month took issue with Santaris Pharma's latest attempt to use a safe harbor provision in US law to fend off patent infringement charges in the companies' ongoing legal war, arguing in a court filing that the legal protection only covers the development o

Pages

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.